Azelaic Acid Powder: Matching the Grade to Your Formulation Route
Disclosure: We may earn a commission if you purchase through links on this page, at no additional cost to you.
Quick Answer
The purchase decision for azelaic acid is not simply whether a listing says 99%. The useful question is whether the powder, analytical method and particle-size profile fit the formulation route you intend to run. A suspension, a glycol-rich clear system and an in-situ neutralized water phase can all start with the same raw material, but they do not impose the same requirements.[1]
For a first cosmetic-grade purchase, confirm identity as azelaic acid (CAS 123-99-9), the assay basis and test method, a lot-specific COA, moisture or loss on drying, residual solvents and microbiological limits where relevant, packaging, and particle-size data. If the formula must stay clear, ask for solubility data in the exact solvent system; a generic water soluble statement is not enough. If the formula will be a suspension, ask for particle-size distribution, milling history and redispersibility instead.
The buyer should also record what is not stated. Many public listings show a 99% headline, an MOQ and a package size but do not disclose D50/D90 distribution, crystal form, residual-solvent profile or a representative batch COA. Those omissions do not prove the material is unsuitable. They mean the listing has not yet answered the formulation question. For the broader supplier-comparison workflow, see the companion guide Azelaic Acid Sourcing for Formulation Buyers.
Why the Same Powder Leads to Different Formulas
Azelaic acid is a saturated nine-carbon dicarboxylic acid. It is widely used in topical products, but its aqueous solubility is limited. A 2025 study describes water solubility of roughly 0.24 g per 100 g at 25 degrees Celsius and notes that many conventional preparations therefore retain much of the active in suspension. Other technical sources report different values at different temperatures, which is not automatically contradictory: temperature, measurement method, grade and solution conditions all matter.[1,2]
That physical behavior creates three practical routes:
- Crystal suspension. Dispersion, wetting, particle size and sedimentation control are central. The buyer is buying a powder whose physical form must survive milling, dispersion and storage.
- Solvent-led clear system. The solvent ratio must remain sufficient after water, humectants and other raw materials are added. Failure typically appears as crystallisation during cool-down or dilution.
- Partial or substantial neutralization. Water compatibility improves, but pH, salt balance and the proportion of undissociated acid change. The delivery form is no longer the same material as the parent acid.
These routes should not be presented as interchangeable versions of one formula. The raw-material specification should follow the route, not the other way around.[3,4]
Choose the Raw Material Around the Delivery Route
| Formulation route | What the buyer controls | Raw-material questions | Common failure signal |
|---|---|---|---|
| Crystal suspension | Wetting, uniformity, sedimentation, skin feel | Particle-size distribution, milling process, bulk density, dispersion-aid compatibility, redispersibility | Grit, hard settling, phase separation or dose non-uniformity |
| Solvent-led clear system | Keeping the active dissolved after dilution and cooling | Solubility in the chosen glycol or ether, water tolerance, heat history, crystallisation data | Clear at hot fill but crystals appear during cooling or storage |
| Neutralized water phase | Water compatibility without losing the intended pH and acid balance | Neutralization capacity, pKa context, salt formation, final pH, crystallisation risk after acidification | pH drift, crystals return, or the formula no longer matches the intended active form |
| Delivery system or particle engineering | Apparent solubility or skin deposition | Carrier identity, loading, release data, particle-size method, finished-system stability | Raw assay looks acceptable but delivery and stability data are absent |
Do Not Treat 99 Percent as a Complete Specification
The percentage on a listing can refer to a specification limit, a reported batch result, an HPLC area percentage, an as-is assay or a dried-basis assay. Those are not equivalent. Ask the supplier to define the field and provide the method reference. If a COA says purity 99% but the specification does not identify the technique or basis, keep the field recorded as stated but unresolved.
Identity errors deserve attention because azelaic acid is also sold into industrial and pharmaceutical channels. Confirm the name, CAS 123-99-9, molecular formula where supplied, appearance and the intended grade. Do not accept a listing that mixes azelaic acid with a derivative, salt, ester or unrelated brightening material under one generic title.
For a powder used in a suspension, particle size can matter more than a small difference between 98% and 99%. Request the measurement technique, sample preparation, D10/D50/D90 if available, and whether the reported distribution applies to the same production lot. A particle-size value without method and lot context is a lead, not a release specification.
Interpreting a Claim That the Powder Is Water Soluble
Water soluble is not a sufficiently precise answer for azelaic acid. It may mean that a small test quantity dissolves at a stated temperature, that a neutralized salt is being described under the parent ingredient name, that a carrier or delivery system is present, or simply that the supplier expects the buyer to use a co-solvent.
Ask what material was tested, at what concentration, in what water quality, at what temperature and pH, and whether the result was a clear solution or a dispersion. The distinction matters because a formula can look clear immediately after heating and then crystallise when the solvent phase is diluted or cooled. A supplier solubility number is a property of a defined test system, not a universal property of every finished base.
The same discipline applies to micronized, nano, instant soluble and fast absorption language. Those terms may describe a process, a particle-size range, a carrier system or a marketing position. They should not be converted into technical claims without an identity statement, a measurement method and a document showing what was actually tested.
Keep the Parent Acid Separate from Salts and Derivatives
A buyer can change handling and delivery behavior by changing the chemical form. Sodium azelate, potassium azelate, ester derivatives, encapsulated systems and other modified materials may have different water compatibility, pH behavior, molecular identity and analytical methods. They can be useful alternatives, but they are not interchangeable with azelaic acid powder simply because the listing uses the same skin-benefit language.
When a supplier proposes a more soluble alternative, ask for the exact INCI or commercial name, CAS number, molecular formula, active-content basis and the way the material should be declared in the finished formula. If the proposed material is a blend or carrier system, request the composition range and the amount of actual azelaic-acid equivalent. This prevents a clear or low-viscosity formula from being compared with a conventional suspension as though only the processing method had changed.
It is also why a finished-product percentage cannot be read back into the raw-material specification. A 10%, 15% or 20% finished preparation may contain suspended crystals, dissolved material, a partially neutralized fraction, a delivery carrier or a combination. The finished percentage alone does not tell the buyer which raw powder, solvent system or analytical release test is appropriate.
Run a Small Formulation Pilot Before a Commercial Order
Do not qualify the powder only by appearance or by dissolving a spoonful in water. Use the intended route and record the variables that can change the result: order of addition, temperature, mixing energy, hold time, solvent-to-water ratio, neutralizer, pH, cooling profile, viscosity and package headspace.
- Request a traceable sample and the matching COA, and record the lot number before testing.
- Run a small batch at the intended use level and at one deliberately lower level, to see whether a failure is concentration-dependent.
- For a suspension, measure initial uniformity, sedimentation, redispersibility and particle feel after the planned storage interval.
- For a clear system, inspect the formula after hot processing, after cooling, after freeze-thaw or accelerated storage as appropriate, and after dilution with the final water phase.
- Measure pH at the same temperature and time point. Do not compare a supplier's saturated-solution pH with the pH of the finished formula.
- Compare the sample result with the commercial lot documents before approving a repeat order. A passing sample does not automatically qualify every future lot.
Two Current Sourcing Leads
The two product links below are sourcing leads, not quality rankings. Both were confirmed to land on the Product IDs shown. Public prices, review counts and statements that a COA is available are commercial signals, not independent quality evidence, and must be rechecked against the exact lot.
A product listing and a supplier storefront are different routes and are not interchangeable.
Questions to Send in the RFQ
- Please confirm azelaic acid identity, CAS 123-99-9, cosmetic grade and the exact product code.
- Is the stated 99% a specification limit, HPLC area purity, an as-is assay or a dried-basis assay? Please provide the method.
- Please provide a recent lot-specific COA, TDS and SDS for the proposed grade.
- For suspension use, please provide particle-size distribution, test method, bulk density and any milling or micronization statement.
- For clear or solvent-led use, please provide solubility data in the proposed solvent and any crystallisation observations after cooling.
- Please confirm sample size, MOQ, package material, shelf life, storage conditions, lead time and change-notification process.
- Please confirm whether the quoted material is manufactured by the named company or supplied through a trading entity, and whether the COA issuer matches the shipped lot.
When a Listing Should Stay Out of the Shortlist
Pause the candidate when the title says azelaic acid but the CAS, formula or product description points to a salt, ester or unrelated material. Pause it when the page shows 99% but cannot explain whether that is an assay, an area purity or a generic marketing number. Pause it when the displayed price is tied to an unlabelled sample pack, when MOQ and package size contradict each other, or when the supplier cannot connect the COA issuer to the entity that will ship the lot.
A short listing is not automatically a bad listing. The issue is whether the missing field blocks the buyer decision. Missing particle-size data may be acceptable for an early supplier conversation if the buyer only wants a solvent-led route and will run a sample. Missing identity, CAS or lot traceability is a different category: those gaps prevent meaningful qualification and should keep the candidate from being treated as a primary offer.
Bottom Line
A suitable azelaic acid raw material is the one that remains identifiable, documentable and processable in the formula you actually plan to make. A 99% cosmetic grade claim is a starting filter. It is not a dispersion specification, a solubility guarantee or evidence that a clear serum will remain clear.
Compare these two leads by role rather than by headline price: one offers the stronger public continuity and sales signal, the other a lower stated MOQ and a more explicit commercial format. Neither should be released for production without the exact lot COA, the missing route-specific data and a small formulation pilot.
References
- Petrovici AG, et al. A Comprehensive Review of Azelaic Acid Pharmacological Properties, Clinical Applications and Innovative Topical Formulations. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12472904/
- Fang Y, et al. A hydrogel miscible azelaic acid-ionic liquids for the treatment of acne vulgaris: enhanced solubility and skin retention. MedComm Biomaterials and Applications. 2025. https://onlinelibrary.wiley.com/doi/10.1002/mba2.70000
- Arpa MD, Biltekin Kaleli SN, Dogan N. Hydroxypropyl-beta-Cyclodextrin-Enhanced Azelaic Acid Hydrogel for Acne Treatment. Journal of Pharmaceutical Innovation. 2025;20:106. https://link.springer.com/article/10.1007/s12247-025-10020-9
- US Patent 5,925,679. Topical vehicles containing solubilized and suspended azelaic acid. https://patents.google.com/patent/US5925679A/en
Related content
Continue exploring related ingredient research and sourcing guides.
Azelaic Acid Sourcing Guide for Formulation Buyers
A buyer-side guide to azelaic acid (CAS 123-99-9) sourcing: identity, 99% assay basis, particle size and dispersion, pH and irritation control, COA package and regulatory boundaries.
Creatine Monohydrate 200 Mesh vs Micronized: What Buyers Should Verify
A 200-mesh claim and the word micronized are both shorthand. What each one can and cannot tell you, when sieve analysis is enough, and how to write a particle-size limit that a lot has to meet.
80 Mesh vs 200 Mesh Creatine Monohydrate: How Buyers Should Specify Particle Size
Mesh is a sieve shorthand, not a specification. How to make 80 and 200 mesh comparable, test dispersion at the intended dose, and write a particle-size limit into the RFQ.
L-Carnitine L-Tartrate COA: How to Read a 99% Assay and a 68% L-Carnitine Result
A salt assay near 99% and an L-carnitine result near 68% can describe the same pure material. How to name the analyte, the basis and the method so a COA actually releases a lot.